VC-backed AbCellera seeks up to C$500m from IPO: Reuters
Vancouver biotech company AbCellera's IPO nets $556M | Venture
Pre-IPO: Everything You Need To Know About AbCellera (Part I) (NASDAQ:ABCL) | Seeking Alpha
IPO Launch: AbCellera Biologics Readies $357 Million IPO - IPOs On TheStreet - U.S. IPO Research & Opinion
AbCellera: Why I Don't Love This Drug Discoverer's Business Model (NASDAQ:ABCL) | Seeking Alpha
IPO: AbCellera Biologics
AbCellera Announces Pricing of Initial Public Offering | Business Wire
Covid-19 Treatment Developer AbCellera Biologics Files for IPO - Bloomberg
IPO Stock AbCellera Eyes Profitability As Covid-19 Antibody Sales Soar | Investor's Business Daily
AI drug discovery platform AbCellera prices upsized IPO at $20, above the upwardly revised range - Renaissance Capital
AbCellera, tapped by Lilly for its COVID-19 antibody therapy, sets IPO terms with $5B valuation | Fierce Biotech
Vancouver-based AbCellera Goes Public on Nasdaq with Massive US $555.5M IPO, Company's Market Value Triples to $15.7 Billion on 1st Day | T-Net News
AbCellera - Products, Competitors, Financials, Employees, Headquarters Locations
AbCellera Biologics to raise up to US $391M from NASDAQ IPO at up to US $4.52B valuation - Private Capital Journal
/cloudfront-us-east-1.images.arcpublishing.com/tgam/SXPTX25NH5BV5HCRRZ2OZZOU3Y.jpg "With historic financing, AbCellera becomes champion of Canada's surging biotechnology sector - The Globe and Mail")
With historic financing, AbCellera becomes champion of Canada's surging biotechnology sector - The Globe and Mail
AbCellera boosts IPO target second time in a week, seeking to raise US$483 - Technology | Business in Vancouver
Pacific Trader: How AbCellera's stock can make a full recovery - BCBusiness
Pre-IPO: Everything You Need To Know About AbCellera (Part I) (NASDAQ:ABCL) | Seeking Alpha
Vancouver-based AbCellera Goes Public on Nasdaq with Massive US $555.5M IPO, Company's Market Value Triples to $15.7 Billion on 1st Day | T-Net News
IPO Alert: AbCellera Biologics (ABCL)
COVID-19 Antibody Discovery Company Preps for Massive $391 Million IPO | BioSpace
